The FDA's drug approvals database lists a supplemental action dated 21 October 2026 on Pfizer's new drug application for linezolid, marketed as Zyvox. The record available to this desk does not state what the supplement changes — it may be a labelling update, a manufacturing change or another administrative revision.
Supplements of this kind are frequent and most do not alter how the drug should be prescribed. Until the revised label is published, there is no new safety finding to act on, and prescribing should follow the current label and local guidance.
- No change to linezolid prescribing follows from this record alone.
- Check the updated FDA label when published if you prescribe linezolid regularly.
- Continue standard monitoring for myelosuppression and drug interactions.
Why it matters
It flags that the label may change, so regular prescribers know to check it.
Don't overread it
A licence supplement is not a new indication or a safety warning; its content is not yet known.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free